Venkat Kumar G, Jeyanthi V, Ramakrishnan S
Department of Biotechnology, Ponnaiyah Ramajayam Institute of Science and Technology, Thanjavur, 613403, Tamil Nadu, India.
Department of Biotechnology, SRM Arts and Science College, Kattankulathur, Chengalpattu District, 603203, Tamil Nadu, India.
New Microbes New Infect. 2020 Apr 20;35:100682. doi: 10.1016/j.nmni.2020.100682. eCollection 2020 May.
The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.
新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在中国武汉出现，引发了一场全球性的呼吸道疾病大流行（新冠肺炎）。截至2020年4月7日，SARS-CoV-2已在全球感染了超过136万人，并导致超过75900人死亡。迄今为止，抗疟疾药物羟氯喹被发现是SARS-CoV-2的一种治疗选择。除了支持性治疗，如中度病例的氧气供应和重症患者的体外膜肺氧合，针对这种疾病的独特药物也在研究中。在此，我们综述了抗体疗法可能是紧急预防和SARS-CoV-2治疗的一种即时策略。
